1 / 41

DRUGS IN HEART FAILURE

DRUGS IN HEART FAILURE. Mari Fotherby & Emma Clingan Heart Failure Specialist Nurses Gloucestershire Heart Failure Service. Introduction. Drug management aims to provide symptomatic relief for the patient while also preventing further deterioration in cardiac function

kaili
Télécharger la présentation

DRUGS IN HEART FAILURE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DRUGS IN HEART FAILURE Mari Fotherby & Emma Clingan Heart Failure Specialist Nurses Gloucestershire Heart Failure Service

  2. Introduction • Drug management aims to provide symptomatic relief for the patient while also preventing further deterioration in cardiac function (Cowie & Kirby, 2003)

  3. The Vicious Cycle of Heart Failure CARDIAC INJURY Pump failure • Vasoconstriction • Na+ H2O retention NeurohormonalActivation Renin Angiotensin, Aldosterone system Sympathetic Nervous system Others e.g. Natriuetic peptides

  4. Diuretics • Effective at treating & controlling fluid retention, but do not prevent disease progression. • If used alone can stimulate renin-angiotensin system & accelerate disease process (SOLVD trial 1991). • No randomised trials to support

  5. Uses • Goal to achieve dry weight – using as low a dose of diuretic as possible. • Titrate to weight & symptoms • Flexible regime • Self management / titration

  6. Loop Diuretics • Furosemide & Bumetanide • Reduce symptoms of congestion by reducing preload • Act on Ascending Loop of Henle to increase the secretion & inhibit reabsoprtion of Na, Chloride and H2O • Long term use lowers B/P by arteriolar vasodilatation • Less likely to cause worsening renal function than Thiazides • Heart Failure Guidelines – 3 day increases.

  7. Thiazide Diuretics • Bendroflumethiazide or Metolazone • Prevent Na reabsorption by kidneys • Cause reduced blood volume • Long-term use lowers B/P, by arteriolar vasodilatation

  8. Cautions with Diuretics • Hyponatraemia • Hypokalaemia & low Mg • Hypovolaemia & hypotension • Drug Interaction – reduce hypoglycaemic effect of oral hypoglycaemics > hyperglycaemia Increased concentration Lithium • Gout • Concordance • Long-term resistance

  9. ACE Inhibitors • Cornerstone of heart failure management • Blockade of the renin-angiotensin-aldosterone system • Decrease cardiac preload & afterload • Prevention of ventricular remodelling

  10. ACE Inhibitors…2 • Approximately 7000 patients evaluated in placebo-controlled clinical trials • Consistent improvement in cardiac function, symptoms and clinical status • Decrease in all-cause mortality by 20-25% • Decrease in combined risk of death and hospitalisation by 20-25%

  11. Clinical Trials • CONSENSUS- Enalapril 1987 • SOLVD- Enalapril 1991 • SAVE- Captopril 1992 • AIRE - Ramipril 1993 • ATLAS- Lisinopril 1999 • HOPE – Ramipril 2000

  12. Effects • Symptomatic improvement may take weeks • Most benefit to more severe LVSD/NYHA class • Benefit to asymptomatic LVSD • Slow up titration, no less than 2 weekly until optimum dose or target achieved

  13. Management • At least 20% of patients with chronic heart failure are not receiving ACE Is • About 10% of these are due to ACE I intolerance • Sell benefits- RARELY necessary to discontinue completely • Glos. Heart Failure Service 2005- 92.2%

  14. Managing Complications • Cough (decreased catabolism of bradykinin) • Hypotension ??symptomatic, discontinue nitrates, calcium channel blockers, ?reduce diuretic dose • Taste disturbance • Seek specialist advice before stopping

  15. Managing Renal Complications • Deteriorating renal function- eGFR!!! • Some deterioration is inevitable with chronic heart failure • Get broad parameters agreed at outset • ?remove NSAIDS, nitrates, calcium channel blockers • ?reduce diuretics (ACE I is alternative pathway for Na & water retention • Treat the patient, not the blood test

  16. Angiotensin II Receptor Blocker • Block the renin-angiotensin system directly at the angiotensin II receptor level • complete blockade of the effects of angiotensin II- vasodilatation • CHARM study (2003) Candesartan, licensed for the treatment of heart failure

  17. Indications • To date, ARBs are not superior to ACE inhibitors • Lack the bradykinin-related side effects of ACE I • Used if the patient is intolerant of an ACE Inhibitor due to a persistent cough or angioedema • ??combination therapy- little evidence/experience (Val-HeFT, 1999)

  18. Beta Blockers • Activation of the sympathetic nervous system is a contributory factor in the pathophysiology of heart failure. • Beta Blockers prevent stimulation of the sympathetic nervous system by inhibiting the action of catecholamines (noradrenaline and adrenaline) at beta-adrenergic receptors.

  19. Beta Adrenergic Blockers can be selective or non-selective. • Nonselective e.g. Carvedilol, Labetolol, Sotalol, Propranolol, affect receptors at Beta1 sites (mainly heart) ,and Beta2 sites (bronchi, blood vessels, and uterus). • Selective e.g. Bisoprolol, Metoprolol, Nebivolol and Atenolol, affect primarily Beta1 sites (heart).

  20. Action • Increase peripheral vascular resistance • Decrease B/P • Reduce heart rate, automaticity and excitability (reduce arrhythmias) • Slow conduction through A-V node • Decrease force of contraction • Decrease Myocardial Oxygen consumption • Constriction of bronchioles • Constriction of peripheral blood vessels

  21. Effects In Heart Failure • Reduce mortality and morbidity • Improve Left Ventricular function & symptoms • Reduce hospital admissions • Aim nationally for 70 – 80% • Glos. Heart Failure Service 2005 – 58%

  22. Trial Evidence • CIBIS I - Bisoprolol improves LV function • CIBIS II -1999 • MERIT - HF, 1999 - Metoprolol – reduce morbidity & mortality; reduce healthcare costs in mild - mod heart failure. • COPERNICUS study, 2001 - use of Carvedilol in severe HF. 35% survival benefit • COMET study, 2003 - suggests Carvedilol vs Metoprolol increases mortality. • SENIORS, 2005 - Placebo vs Nebivolol

  23. Indications • LVSD on ECHO • Mild to Severe LVSD of ischaemic or non –ischaemic aetiology • Clinically stable – no fluid • Can precipitate Asthma, but can be tolerated in COPD if have reversible airways disease -HFS/Cardiologist. • Drug interactions possible • Heart rate, ECG >60; B/P >100 mmHg • Bisoprolol used if ongoing ischaemia

  24. Patient Advice • Bisoprolol 1.25 mg – 10 mg daily • Carvedilol 3.125 BD to 25mg BD* • Slow up titration, 2 – 4 weekly, from small initial dose to target or max tolerated dose – SOME is better than none. • Informed consent • Initial symptomatic deterioration possible • Long term benefits • Encourage self monitoring • Regular follow up and access for advice

  25. Managing Complications • Worsening Heart Failure - up diuretics • Worsening breathlessness (bronchospasm related) • Symptomatic Hypotension- look at other meds before reducing B-Blocker. • Excessive Bradycardia • Fatigue; cold extremities; sleep disturbance • Glucose tolerance in Diabetics

  26. Spironolactone • Aldosterone plays an important role in the pathophysiology of heart failure • Aldosterone has adverse effects on cardiac structure and function • Low dose spironolactone (aldesterone antagonist) reduces mortality in moderate to severe heart failure patients (RALES mortality trial, 1999)

  27. Indications • NYHA class III-IV • Despite optimal treatment • Irrespective of aetiology • ??same effect on mild LVSD (NYHA class II) or asymptomatic LVSD • Glos. Heart Failure Service 2005- 73%

  28. Management • Starting dose 12.5mg OD • Close monitoring of K+ & renal function (bloods 10, 20, 30 days) • Increase dose to 25mg OD if tolerated (bloods 10,20,30 days) • Inform GP need to check bloods every 4/52 for 3/12, 3/12 for 1 year, 6/12 thereafter- IMPORTANT

  29. Complications • Discontinue and seek advice if: • Creatinine >200 (or 30% from baseline) • Potassium  to >5.5 • Potassium 5-5.5 reduce dose by 50% • Monitor for signs of sodium & water depletion e.g. diarrhoea & vomiting

  30. Complications…2 • Gynaecomastia- 10% in the RALES study • May need to be discontinued • Consider Eplerenone (EPHESUS, 2003)- same precautions and side effects • Starting dose of 25mg Od, aiming to increase to 50mg Od after 4 weeks • Close monitoring of renal function applies

  31. Digoxin • Cardiac glycosides are indicated in AF to control ventricular rate • In sinus rhythm it is recommended to improve clinical status of patients with persisting HF symptoms despite optimum treatment • Most benefit to pts with more severe HF

  32. Management • DIG Trial/ESC guidelines (2001)- ↓risk of hospitalisations without an impact on survival • Monitor heart rate (especially when used with beta blockers) but do not withdraw suddenly • Drug interactions

  33. Digoxin Toxicity • In the elderly the signs & symptoms may be less specific • Falls, confusion, ↓mobility- reduce dose • Monitor renal function- this can lead to dig toxicity • Digoxin induced arrhythmias are common in hypokalemic patients

  34. Hydralazine with Nitrate • For patients truly intolerant of ACE / ARB • Hypertensive • Symptomatic despite therapy

  35. Morphine • Relief of breathlessness in pulmonary oedema & left sided heart failure • Acts by peripheral dilatation and decreasing afterload • Renally excreted • Side effects • Not only for palliative care!

  36. Concordance • About ½ of the medicines prescribed for patients with long term conditions are not taken as prescribed • Poor treatment adherence = worsening HF symptoms • More tablets= greater the risk of non-adherence • ? Dosette box- but remember extra diuretics

  37. Remember… • Is continence an issue? • Dizziness? • Gout? • Hyperglycaemia? • Taste disturbance? • Cognitive impairment? Simplify the regime • Social isolation?

  38. Heart Failure Service • Heart Failure Nurse can play pivotal role in drug management • Specialist knowledge in initiating & titrating HF medications • Monitoring – home & clinic • Patient education • Nurse Prescribing • Communication with multidisciplinary team

  39. Any Questions?

More Related